Updated:
Sensei Biotherapeutics
Sensei Biotherapeutics, led by CEO John Celebi, develops pH-restricted antibodies for immuno-oncology from its Boston headquarters.
Sensei Biotherapeutics
Sensei Biotherapeutics was founded in 1999 as a private biotech developing immunotherapeutic cancer vaccines. After plateauing through the early 2010s, the company recapitalized and went public via a SPAC merger in February 2021, raising approximately $150 million to fund a new strategic direction under CEO John Celebi. The wealth backing the firm is institutional and public-market in nature, not tied to a single-family fortune. Celebi's leadership marked a clean break from the legacy vaccine approach. The current pipeline is built around the ImmunoPhage platform, which engineers bacteriophages to deliver tumor antigens and stimulate T-cell responses. Lead programs include SNS-101, a pH-selective antibody targeting VISTA (V-domain Ig suppressor of T-cell activation), a checkpoint previously considered undruggable at physiological pH. A Phase 1/2 clinical trial for SNS-101 began dosing patients in 2022. The firm also maintains a preclinical program, SNS-102, targeting a second undisclosed checkpoint. Assets are concentrated in the United States, with clinical trial sites spanning oncology research centers in North America. As a public reporting entity, Sensei disclosed $100.9 million in cash and equivalents as of year-end 2023. The company operates from a single headquarters in Boston, Massachusetts, and files quarterly with the SEC. There are no disclosed adjacent family-office vehicles, philanthropic foundations, or co-investor clubs. In April 2024, the firm presented updated Phase 1 data for SNS-101 at the American Association for Cancer Research annual meeting, showing a manageable safety profile and early signs of clinical activity. Sensei's structural differentiator is its biologic platform targeting pH-specific conformations of immune checkpoints. This pH-restricted binding mechanism represents a genuine scientific moat: it allows the antibody to engage its target only in the acidic tumor microenvironment, potentially avoiding the systemic immune toxicity that has plagued earlier checkpoint inhibitors aimed at the same pathway.
General information
Firm type
Asset Manager
Year founded
1999
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
John Celebi
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at Sensei Biotherapeutics?
President and CEO John Celebi has led the company since the 2021 SPAC merger that took it public. He reoriented the pipeline from legacy cancer vaccines to the current pH-restricted antibody platform. The board of directors, which includes venture investors from the pre-SPAC era, governs major financial commitments. Day-to-day capital allocation is overseen by the executive management team.
Is Sensei structured as a family office or a biotech operating company?
Sensei Biotherapeutics is a publicly traded biotech operating company listed on Nasdaq under the ticker SNSE. It is not a family office, multi-family office, or investment vehicle. The firm uses public equity capital to fund its own internal drug discovery and clinical development programs.
What scientific mechanism differentiates Sensei's lead program?
SNS-101 is a monoclonal antibody that binds VISTA only in acidic conditions typical of the tumor microenvironment. VISTA has been a challenging checkpoint target because blocking it systemically at normal physiological pH can cause severe immune-related side effects. The pH-restricted binding mechanism is designed to deliver efficacy at the tumor site while minimizing systemic toxicity.
How does Sensei's ImmunoPhage platform work?
The ImmunoPhage platform uses engineered bacteriophages — viruses that infect bacteria — to deliver tumor-specific antigens directly to antigen-presenting cells. This is intended to generate a robust T-cell response against the cancer. The platform was the foundation of the company's original technology prior to the strategic shift toward antibody-based therapeutics.
What is Sensei Biotherapeutics' current financial position?
As a publicly traded company, Sensei reported $100.9 million in cash, cash equivalents, and marketable securities as of December 31, 2023 (per the firm's SEC filings). The company does not disclose an AUM figure. It is financed through public equity markets, not a family fortune or limited-partner commitments.
Does Sensei participate in external fund commitments or direct biotech investments?
Sensei does not operate as an investment vehicle. It does not make fund commitments to outside GPs or participate in venture-stage biotech syndicates. All capital is deployed internally toward its own research, clinical trials, and corporate operations.
In which clinical indications is Sensei testing its lead drug candidate?
The Phase 1/2 clinical trial for SNS-101 is enrolling patients with advanced solid tumors. The study evaluates safety, tolerability, and preliminary efficacy both as a monotherapy and in combination with a PD-1 checkpoint inhibitor. Specific tumor types have not been segmented into separate cohorts in the publicly disclosed trial design.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: